If Einstein was still alive – who would he vote for ?

Walgreens paying $106.8 million to settle US prescription billing fraud charges

Walgreens paying $106.8 million to settle US prescription billing fraud charges https://www.reuters.com/legal/government/walgreens-paying-1068-million-settle-us-charges-over-prescription-billing-fraud-2024-09-13/ Sept 13 (Reuters) – Walgreens Boots Alliance (WBA.O) , opens new tab agreed to pay $106.8 million to settle charges it fraudulently billed the U.S. government for prescriptions that were never dispensed, the Department of Justice said on Friday. The Justice Department said […]

Pain med prescriptions did not cause opioid epidemic courts rule

Pain med prescriptions did not cause opioid epidemic, courts rule

PBM reform: The end of the beginning

PBM reform: The end of the beginning https://chaindrugreview.com/pbm-reform-the-end-of-the-beginning/ The recent release of an interim report by the Federal Trade Commission about what the agency characterizes as “prescription drug middlemen” represents a vindication of sorts for pharmacy advocates who have long contended that PBMs employ business practices that skew the market to their advantage. Following the […]

Is this what “covert genocide” looks/sounds like

Humana prepares for ‘frustration’ over Medicare Advantage changes, 13 market exits

Humana prepares for ‘frustration’ over Medicare Advantage changes, 13 market exits https://www.beckerspayer.com/payer/theres-going-to-be-a-lot-of-frustration-humana-prepares-for-medicare-advantage-market-exits-benefit-changes.html Humana will stop offering Medicare Advantage in 13 counties in 2025, CFO Susan Diamond said Sept. 4. Speaking at an investor conference, Ms. Diamond said the company will no longer offer several plans in 2025. The exits will affect around 560,000 beneficiaries, 10% of […]

US allows increased production of Takeda’s ADHD drug to address shortage

US allows increased production of Takeda’s ADHD drug to address shortage https://www.reuters.com/business/healthcare-pharmaceuticals/us-allows-increased-production-takedas-adhd-drug-address-shortage-2024-09-04/ The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s (4502.T) ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States. The raised production limit follows the Food and […]